Author:
Christoph A.,Werdan K.,Müller-Werdan U.
Reference20 articles.
1. Baue AE, Faist E, Fry DE (2000) Multiple organ failure — pathophysiology, prevention and therapy. Springer, New York Berlin Heidelberg
2. Bodmann KF, Vogel F (2001) Antimikrobielle Therapie der Sepsis — Empfehlungen einer Arbeitsgruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Chemother J 10:43–55
3. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873 and Intensive Care Med 30:536–555
4. Expertenforum: Burchardi H, Briegel J, Eckart J, Hasenfuß G, Hermann HP, Holtz J, Meier-Hellmann A, Mölhoff T, Radermacher P, Roessler M, Spies C, Thiemermann C, Werdan K (2000) Hämodynamisch aktive Substanzen in der Intensivmedizin. Anästhesiologie & Intensivmedizin 41:560–631
5. Kuhn C, Müller-Werdan U, Schmitt DV, Lange H, Pilz G, Kreuzer E, Mohr FW, Zerkowski HR, Werdan K (2000) Improved outcome of APACHE II score-defined escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared to 1988–1990: The ESSICS-study pilot project. Eur J Cardiothor Surg 17:30–37